On May 17, 2017 bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, reported that updated interim data from its study of bb2121, the company’s anti-BCMA CAR T cell therapy will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois (Press release, bluebird bio, MAY 17, 2017, View Source;p=RssLanding&cat=news&id=2273747 [SID1234519182]). bb2121 is currently being studied in a Phase 1 trial in patients with relapsed/refractory multiple myeloma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Know more, wherever you are:
Latest on Cancer Drug Development at ASCO (Free ASCO Whitepaper), book your free 1stOncology demo here.
"This past November we presented the initial clinical data from the first three dosing cohorts in this ongoing Phase 1 study of bb2121 in patients with relapsed/refractory multiple myeloma. At ASCO (Free ASCO Whitepaper) in June, we look forward to presenting data on those same patients with longer follow-up, as well as safety and efficacy data on an additional 9 patients treated subsequently." said David Davidson, M.D., chief medical officer, bluebird bio. "These data will advance our understanding of the bb2121 risk-benefit profile and inform planning with our partners at Celgene for the dose expansion cohort of this study, and the design of a potential pivotal study."
First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma: Updated Results (Abstract #3010).
Presenter: Jesus G. Berdeja, M.D., Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
Date: Monday, June 5, 2017, 4:45-6:00 pm CT (poster discussion); 8:00-11:30 am CT
Location: Hall D1
Session Title: Poster Discussion Session: Developmental Therapeutics—Immunotherapy
The event and live webcast will begin at 6:30 p.m. CT (7:30 p.m. ET) on Monday, June 5. To access the live webcast, please visit the "Events & Presentations" page within the Investors and Media section of the bluebird bio website at View Source Replays of the webcast will be available on the bluebird bio website for 90 days following the event.